Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma
Authors:
Top Cited Papers
Open Access
- 16 October 2024
- journal article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (1) , 132-142
Abstract
No abstract availableKeywords
Funding Information
- Regeneron Pharmaceuticals Inc
- Sanofi US
This publication has 22 references indexed in Scilit:
- Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic TherapiesChest, 2023
- Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatmentAnnals of Allergy, Asthma & Immunology, 2023
- Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with BenralizumabAdvances in Therapy, 2022
- Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe AsthmaChest, 2022
- Defining a Severe Asthma Super-Responder: Findings from a Delphi ProcessThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Remission and Changes in Severity Over 30 Years in an Adult Asthma CohortThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- The Relationship of Asthma Biologics to Remission for AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- An expert consensus framework for asthma remission as a treatment goalJournal of Allergy and Clinical Immunology, 2020
- A review on the pathophysiology of asthma remissionPharmacology & Therapeutics, 2019
- Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control QuestionnaireRespiratory Medicine, 2006